The role of pharmacotherapy in the treatment of metabolic syndrome - Galdos Riveros, Alvaro Carlos;Souza Moura, Eliane;da Silva Lima, Evillin
26,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
13 °P sammeln
  • Broschiertes Buch

Metabolic syndrome (MS) can be characterised by a group of risk factors for cardiovascular disease, related to central fat distribution and insulin resistance. Obesity is growing rapidly and is directly related to MetS and some of its complications include type II diabetes mellitus, hypercholesterolaemia and hypertension. Treatment for MetS is based mainly on lifestyle changes to reduce weight and, if necessary, drug therapy to treat hypertension, diabetes mellitus and dyslipidaemia, as these are considered risk factors for cardiovascular disease (CVD).

Andere Kunden interessierten sich auch für
Produktbeschreibung
Metabolic syndrome (MS) can be characterised by a group of risk factors for cardiovascular disease, related to central fat distribution and insulin resistance. Obesity is growing rapidly and is directly related to MetS and some of its complications include type II diabetes mellitus, hypercholesterolaemia and hypertension. Treatment for MetS is based mainly on lifestyle changes to reduce weight and, if necessary, drug therapy to treat hypertension, diabetes mellitus and dyslipidaemia, as these are considered risk factors for cardiovascular disease (CVD).
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr Alvaro Galdos, a Pharmaceutical Chemist who graduated from the Faculty of Pharmaceutical, Biochemical and Biotechnological Sciences at the Universidad Católica Santa Maria, UCSM (Peru), obtained his master's and doctorate degrees in Sciences from the University of São Paulo (USP). He is currently a professor at the Institute of Health Sciences at the Federal University of Mato Grosso.